Filip Garbicz

3.5K posts

Filip Garbicz banner
Filip Garbicz

Filip Garbicz

@FilipGarbicz

Physician searching for cures.

Boston, MA Katılım Temmuz 2013
560 Takip Edilen538 Takipçiler
Filip Garbicz retweetledi
Filip Garbicz retweetledi
Papa Heme
Papa Heme@Papa_Heme·
Before you call it MDS, check a copper level — vacuolized precursors on the marrow are your clue, and the cytopenias are completely reversible. Who gets copper deficiency? Bariatric surgery patients People who take too much zinc supplements
Papa Heme tweet media
English
14
59
240
11.5K
Filip Garbicz
Filip Garbicz@FilipGarbicz·
@BoWang87 There is a lot of labeling errors in this image. How about we go back to having some human touch in those scientific illustrations? So that they are... correct? This ain't microvilli... Looks like my vitamin D capsule
Filip Garbicz tweet media
English
0
0
5
119
Filip Garbicz retweetledi
Nicholas Hornstein
Nicholas Hornstein@GIMedOnc·
Drug development is supposed to be linear. Build the drug → use the drug → resistance shows up → then figure out what to do next. Aaaand not what Revolution Medicines is doing. 🧬 At #AACR26 they disclosed RM-055, which honestly is a unique concept. Before daraxonrasib is even fully in the world, they’re building around resistance. How it works: • Most mutant RAS proteins are relatively resistant to GAP-mediated hydrolysis • That helps keep RAS in the active state • They’ve found a way to enhance that hydrolysis with RM-055 RM-055 can: • restore hydrolysis in mutant RAS • flatten daraxonrasib-resistant models • generate activity even in RAS-amplified settings 👀 That’s a very smart way to think about this space. Not just “here’s our inhibitor.” More like: we already know resistance to our drug is coming, so let’s start building now. That’s how we cure cancer, not more me-toos (if I hear about another new PD1 program I’m going to cry). @OncoAlert @TheGutOncLab @Onco_Nexus
Nicholas Hornstein tweet mediaNicholas Hornstein tweet media
English
2
41
166
16.3K
Filip Garbicz retweetledi
Yakup Ergün
Yakup Ergün@dr_yakupergun·
One of the most notable studies from #AACR26: Daraxonrasib + gem/nab-paclitaxel shows a strong early signal in 1L mPDAC. ORR 58% DCR 90% 6-month PFS 84%!! Things are finally moving in pancreatic cancer👇 aacrjournals.org/cancerres/arti…
Yakup Ergün tweet media
English
3
39
128
12.3K
Filip Garbicz retweetledi
Jonathan Reiner
Jonathan Reiner@JReinerMD·
Long term follow up of a phase 1 trial of an mRNA tumor vaccine shows that 7/8 patients with pancreatic cancer, who mounted an immune response to the vaccine, are still alive 6 years later. This is breathtaking data and shows the promise of mRNA vaccines. nbcnews.com/health/cancer/…
English
164
2.4K
9.2K
670K
Filip Garbicz
Filip Garbicz@FilipGarbicz·
Our new paper in Nature Communications is out (@NatureComms): How does a single mutation in a ribosomal protein drive blood cancer?
Filip Garbicz tweet media
English
1
0
5
148
Filip Garbicz retweetledi
Nicholas Hornstein
Nicholas Hornstein@GIMedOnc·
RevMed absolutely stole the show at AACR with their Pan-RAS and G12D inhibitors. First line panc, second line NSCLC, even in early trials this is extremely compelling data. 2L NSCLC anti G12D (early data): PFS: 11 months ORR: 52% G3 AEs: 13% (Now compare that to 10 months with Osimertinib in 2L NSCLC)… This can’t be FDA approved soon enough. @OncoAlert @TheGutOncLab
Nicholas Hornstein tweet media
English
8
83
324
22.7K